Physician profile
James L Moore
NPI 1265479471
$3,857.12
in general payments reported to CMS, 2019-2025
25 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $300 · 2021: $362 · 2022: $320 · 2023: $449 · 2024: $784 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,310.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,309.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $718.00 | 2019-2025 | Keytruda, Lynparza |
| Eisai INC. | $666.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $635.79 | 2019-2025 | Jemperli, Zejula |
| Genmab U.S., INC. | $356.82 | 2021-2025 | Tivdak |
| Astrazeneca Pharmaceuticals LP | $353.80 | 2019-2025 | Lynparza, Enhertu |
| Clovis Oncology, INC. | $281.98 | 2019-2022 | |
| Abbvie INC. | $163.05 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $96.02 | 2020-2024 | Mychoice Cdx |
| Tesaro, INC. | $85.27 | 2019 | |
| Tempus Ai, INC | $67.43 | 2024 | |
| Astellas Pharma US INC | $61.86 | 2023-2025 | Veozah |
| Immunogen, INC. | $52.23 | 2023-2024 | Elahere, Elahere |
| Becton, Dickinson and Company | $45.07 | 2022 | |
| Caris Mpi, INC. | $37.53 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $29.54 | 2025 | Datroway |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $27.80 | 2020 | |
| Hologic Sales and Service, LLC | $23.25 | 2025 | Novasure, Myosure Tissue Removal Device |
| Fennec Pharmaceuticals, INC. | $22.98 | 2025 | Fyarro |
| Pharmaand Gmbh | $22.87 | 2025 | Rubraca |
| Pharmacosmos Therapeutics INC. | $22.33 | 2021 | |
| Inari Medical, INC. | $21.55 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Coopersurgical, INC. | $20.29 | 2019 | |
| Helsinn Therapeutics (U.S.), INC. | $17.10 | 2019 | |
| Applied Medical Resources Corporation | $15.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.